MannKind reported $744.4M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Adma Biologics USD 665.18M 40.94M Mar/2026
BioCryst Pharmaceuticals USD 465.05M 49.11M Mar/2026
Eli Lilly USD 116.58B 4.1B Mar/2026
Halozyme Therapeutics USD 2.67B 147.4M Mar/2026
Insmed USD 2.08B 188.7M Mar/2026
Karyopharm Therapeutics USD 108.42M 12.18M Dec/2025
MacroGenics USD 217.87M 38.97M Mar/2026
MannKind USD 744.4M 47.78M Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Novavax USD 1.04B 133.35M Mar/2026
Novo Nordisk DKK 76.18B 412.98B Jun/2025
Pfizer USD 207.62B 542M Mar/2026
Sanofi EUR 128.02B 1.22B Mar/2026
Xencor USD 736.85M 138.65M Mar/2026